تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $9.5B | $9.5B | $9.3B | $8.5B | $8.1B | $7.8B | $6.7B | $6.3B | $5.8B | $5.3B | $4.9B | $4.8B | $4.8B | $4.6B | $4.3B | $4.2B | $3.6B | $2.8B |
| سود ناخالص | $6.7B | $6.7B | $6.4B | $5.8B | $5.5B | $5.3B | $4.5B | $4.1B | $3.8B | $3.4B | $3.1B | $3.0B | $3.0B | $2.8B | $2.7B | $2.5B | $2.1B | $1.7B |
| حاشیه سود ناخالص % | 70.9% | 70.5% | 69.1% | 68.3% | 67.8% | 68.3% | 66.8% | 65.7% | 65.2% | 64.9% | 64.3% | 62.3% | 62.9% | 62.1% | 62.7% | 60.0% | 58.2% | 61.7% |
| سود عملیاتی (EBIT) | $3.6B | $3.6B | $3.4B | $3.1B | $2.9B | $2.8B | $2.3B | $2.0B | $1.9B | $1.7B | $1.4B | $1.1B | $970M | $821M | $854M | $684M | $309M | $281M |
| حاشیه سود عملیاتی % | 37.6% | 38.0% | 36.6% | 35.9% | 36.2% | 36.0% | 34.0% | 32.2% | 32.3% | 32.5% | 28.7% | 22.7% | 20.3% | 18.0% | 19.7% | 16.2% | 8.6% | 10.2% |
| سود خالص | $2.6B | $2.7B | $2.5B | $2.3B | $2.1B | $2.0B | $1.6B | $1.5B | $1.4B | $864M | $821M | $339M | $583M | $504M | $436M | $245M | $110M | ($100M) |
| حاشیه سود خالص % | 27.5% | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% | 7.1% | 12.2% | 11.1% | 10.1% | 5.8% | 3.1% | -3.6% |
| EBITDA | — | $4.1B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.5B | $2.2B | $1.9B | $1.6B | $868M | $1.1B | $1.0B | $941M | $635M | $400M | $2M |
| سود هر سهم (EPS) | $6.07 | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 | $1.01 | $0.87 | $0.51 | $0.23 | $-0.21 |
| سهام منتشرشده (میلیون) | — | 444M | 455M | 462M | 470M | 477M | 479M | 482M | 487M | 493M | 498M | 502M | 502M | 500M | 500M | 482M | 482M | 482M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی ZTS در دسترس است. /companies/us/ZTS
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms